Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.

Auteurs : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F
Jaar : 2023
Journal : J Natl Cancer Inst

Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.

Auteurs : Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F
Jaar : 2022
Journal : Cancer Treat Rev
Volume : 110
Pagina's : 102460

JCOG0603: Are We Really Sure This Was a Negative Trial?

Auteurs : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F
Jaar : 2022
Journal : J Clin Oncol
Volume : 40
Pagina's : 803-805

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.

Auteurs : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F
Jaar : 2022
Journal : Curr Opin Oncol
Volume : 34
Pagina's : 382-388

The Exciting New Field of HER2-Low Breast Cancer Treatment.

Auteurs : Eiger D, Agostinetto E, Saude Conde R, de Azambuja E
Jaar : 2021
Journal : Cancers (Basel)
Volume : 13

Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience.

Auteurs : Franzoi MA, Saude Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E
Jaar : 2021
Journal : Breast
Volume : 57
Pagina's : 86-94